Levalbuterol NLT 98%

Levalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD^[1].
In Vitro: Levalbuterol (10 μM; 24 hours) induces 11β-HSD1 mRNA expression, however, it does not influence 11β-HSD2expression in airway epithelial cells^[1].
Levalbuterol (10 μM; 24 hours) significantly reduces both LPS- and TNF-α-induced NF-κB activity while increasing GRE activation in an 11β-HSD1 dependent manner in a transformed mouse airway epithelial cell line^[1].
In Vivo: Levalbuterol (subcutaneous injection; 1 mg/kg; 14 days) significantly decreases pulmonary inflammation in OVA mice, demonstrated a decrease in eosinophilia and IgE^[3].